US20060275353A1 - Stable topical drug delivery compositions - Google Patents

Stable topical drug delivery compositions Download PDF

Info

Publication number
US20060275353A1
US20060275353A1 US11/506,137 US50613706A US2006275353A1 US 20060275353 A1 US20060275353 A1 US 20060275353A1 US 50613706 A US50613706 A US 50613706A US 2006275353 A1 US2006275353 A1 US 2006275353A1
Authority
US
United States
Prior art keywords
composition
phosphatidylcholine
polyglycol
insulin
macromolecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/506,137
Inventor
Nicholas Perricone
Chim Potini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transdermal Biotechnology Inc
Original Assignee
Nicholas V. Perricone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas V. Perricone filed Critical Nicholas V. Perricone
Priority to US11/506,137 priority Critical patent/US20060275353A1/en
Publication of US20060275353A1 publication Critical patent/US20060275353A1/en
Assigned to TRANSDERMAL BIOTECHNOLOGY, INC. reassignment TRANSDERMAL BIOTECHNOLOGY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PERRICONE, NICHOLAS V.
Priority to US12/796,213 priority patent/US20100311696A1/en
Assigned to PERRICONE, NICHOLAS V. reassignment PERRICONE, NICHOLAS V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: POTINI, CHIM
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/56Protease inhibitors from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins

Definitions

  • the present invention relates to topical drug delivery compositions and methods of transdermal drug delivery. More specifically, the present invention relates to stable drug delivery compositions for topical administration.
  • Topical drug delivery systems are known. These systems deliver drugs, therapeutic agents and other desired substances transdermally and may be designed to act locally at the point of application or to act systemically once entering the body's blood circulation. In these systems, delivery may be achieved by means such as direct topical application of a substance or drug in the form of an ointment or the like, or by adhesion of a patch with a reservoir or the like that holds the drug and releases it to the skin in a time-controlled fashion.
  • Transdermal delivery systems for agents such as drugs, pain relieving compounds, vitamins, and skin improving compounds have been in use for a number of years. These transdermal delivery systems using creams have been developed for use with analgesics and skin refining compounds. Transdermal systems using a patch have been developed for nicotine and estrogen therapies, for instance, estradiol technology described in U.S. Pat. No. 6,521,250 to Meconi, et al.
  • a composition for transdermal delivery of a macromolecule comprises a phosphatidylcholine carrier component entrapping the macromolecule, wherein the carrier component stabilizes the macromolecule at room temperature.
  • a method for administering a drug or other active agent comprises applying to skin composition containing an effective amount of the drug or active agent, a carrier having a phosphatidylcholine component entrapping the drug or active agent.
  • Phosphatidylcholine is used as a carrier for the topical delivery of polypeptides and macromolecules in the practice of this invention.
  • Phosphatidylcholine is a basic component of cell membrane bilayers and the main phospholipid circulating in the plasma.
  • Phosphatidylcholine is highly absorbable and supplies choline which is needed to facilitate movement of fats and oils across and maintain cell membranes in animals.
  • Topical delivery compositions of the present invention are non-polar and formulated to contain polypeptides and macromolecules soluble in phosphatidylcholine, which are then applied to skin for transdermal delivery of the macromolecule.
  • Topical delivery compositions of the invention are efficacious in the delivery of macromolecular drugs that are conventionally administered intramuscularly, intravenously or orally, including, but not limited to polypeptides such as insulin and somatropin, prostaglandins, glucocorticoids, estrogens, androgens, and the like.
  • topical administration of a composition and transdermal delivery of the drug or active agent therein is easier and pleasanter as an administration route than injections, particularly for drugs such as insulin that must be given to patients over a period of time, or for a lifetime. Furthermore, unlike oral administration where a substantial amount of the drug can be destroyed in the digestive process, the drugs in a topical application are not wasted. Topical application allows a steady diffusion of the drug to the desired target area without the cyclic dosages typical of orally or parenterally administered drugs.
  • phosphatidylcholine as used herein means a mixture of stearic, palmitic, and oleic acid diglycerides linked to the choline ester of phosphoric acid, commonly called lecithin.
  • lecithin many commercial lecithin products are available, such as, for example, those sold under the tradenames Lecithol®, Vitellin®, Kelecin®, and Granulestin® because lecithin is widely used in the food industry.
  • Compositions of the invention can contain synthetic or natural lecithin, or mixtures thereof. Natural preparations are preferred because they exhibit desirable physical characteristics and are both economical and nontoxic.
  • Preferred topical delivery compositions of the present invention additionally contain polyenylphosphatidylcholine (herein abbreviated “PPC”) to enhance epidermal penetration.
  • PPC polyenylphosphatidylcholine
  • the term “polyenylphosphatidylcholine” as used herein means any phosphatidylcholine bearing two fatty acid substituents, wherein at least one is an unsaturated fatty acid with at least two double bonds such as linoleic acid.
  • soybean lecithin and soybean fractions for example, contain higher levels of polyenylphosphatidylcholine, with dilinoleoyl-phosphatidylcholine (18:2-18:2 phosphatidylcholine) as the most abundant phosphatidylcholine species, than conventional food grade lecithin, and are useful in formulating topical delivery compositions of the invention.
  • conventional soybean lecithin is enriched with polyenylphosphatidylcholine by adding soybean extracts containing high levels of polyenylphosphatidylcholine.
  • this type of phosphatidylcholine is called “polyenylphosphatidyl-choline-enriched” phosphatidylcholine (hereinafter referred to as PPC-enriched phosphatidylcholine), even where the term encompasses lecithin obtained from natural sources exhibiting polyenylphosphatidylcholine levels higher than ordinary soybean varieties.
  • PPC-enriched phosphatidylcholine polyenylphosphatidyl-choline-enriched phosphatidylcholine
  • Rhône-Poulenc's product is a soybean extract containing about 42% dilinoleoylphosphatidylcholine and about 24% palmitoyllinoleylphosphatidylcholine (16:0-18:2 PC) as the major phosphatidylcholine components.
  • the PPC-enriched phosphatidylcholine forms a bilayer enveloping the polypeptide or macromolecule to create the topical drug delivery composition, contributing to the stability of the active molecule and enhancing penetration.
  • the topical drug delivery composition may be in liquid crystal phase, with the PPC-enriched phosphatidylcholine loosely arranged in multilamellar fashion, with the polypeptide or macromolecule being bonded and entrapped within the lipid bilayers formed therein, as disclosed in U.S. patent application Ser. No. 10/448,632 to Perricone. This forms a loosely arranged, yet stable, PPC-enriched phosphatidylcholine-drug complex that further increases penetration and delivery of the polypeptide or macromolecule to the dermal vasculature.
  • Topical drug delivery compositions of the present invention provide an administration route that is a marked improvement over conventional insulin injections, considerably easier and pleasanter. It is a further advantage that compositions of the invention are also stable at room temperature, providing considerable convenience for insulin users who, in the past, have had to deal with the refrigerated insulin products commercially available. Also, insulin compositions according to the present invention have longer shelf lives (whether stored at room temperature or refrigerated) and will not denature at room temperature as would traditional insulin treatments.
  • Insulin useful in the topical drug delivery compositions of the present invention is commercially available from a variety of sources, marketed under the tradenames Humulin®, Novolin®, Humalog®, Inutral®, among others. Some of these products contain porcine sequences.
  • Compositions of the invention are preferably formulated with recombinant human polypeptides such as those obtained from Sigma Co., Spectrum Chemicals and Laboratories, and similar vendors and employed in the examples that follow. It is an advantage of the invention that topical drug delivery compositions carrying insulin are formulated with commercially available ingredients.
  • Topical drug delivery compositions are generally formulated with a carrier comprising a PPC-enriched phosphatidylcholine material with the trade name NAT 8729 (commercially available from vendors such as Rhône-Poulenc and American Lecithin Company) and at least one polyglycol (polyhydric alcohol of a monomeric glycol such as polyethylene glycol (PEG) having molecular weights of 200, 300, 400, 600, 1000, 1450, 3350, 4000, 6000, 8000 and 20000.
  • a carrier comprising a PPC-enriched phosphatidylcholine material with the trade name NAT 8729 (commercially available from vendors such as Rhône-Poulenc and American Lecithin Company) and at least one polyglycol (polyhydric alcohol of a monomeric glycol such as polyethylene glycol (PEG) having molecular weights of 200, 300, 400, 600, 1000, 1450, 3350, 4000, 6000, 8000 and 20000.
  • PEG poly
  • this carrier may comprise a surfactant such as a siloxylated polyether comprising dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane or silicone glycol copolymer fluid commercially available from vendors such as Dow Corning, e.g. poly(oxyehtylene.oxypropylene) methyl polysiloxanne copolymer sold under the tradename Dow Corning 190 surfactant, and lubricant such as silicone fluids containing low viscosity polydimethylsiloxane polymers, methylparaben (p-hydroxy benzoic acid methyl ester) commercially available from vendors such as Down Corning (under the tradename Dow Corning 200 silicone fluid).
  • a surfactant such as a siloxylated polyether comprising dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane or silicone glycol copolymer fluid commercially available from vendors such as Dow Corning, e.g. poly(
  • purified water may be added to the carrier.
  • the carrier is then mixed with a preparation of the particular polypeptide(s) or macromolecule(s) in an amount to obtain the desired strength in the final composition.
  • Stable insulin topical preparations were formulated by first preparing a base solution.
  • NAT 8729 (45% w/w) was shaved and added to a mixture of polyglycol E200 (50% w/w) and polyglycol E400 (5% w/w) both obtained from Dow Corning.
  • the base solution was then covered well and lightning mixed with a special disintegration head impeller slowly at 800 rpm with slight heat. The temperature did not go above 40° C. Typical mixing times were 5 hours.
  • the final solution is a crystal clear, viscous amber solution with no sediments or separations.
  • the methylparaben was first added to the base solution and mixed for at least an hour until a complete solution formed. Then the Dow Corning 200-5 or 10 cst was slowly added and mixed until a clear solution formed. Afterwards the Dow Corning Fluid 190 was added slowly and mixed into the solution to form the carrier.
  • Insulin preparations of the invention were then made using the carrier in two strengths: 50 units and 100 units, by simply dissolving RNA-derived recombinant human insulin obtained from Sigma into the carrier. It was readily soluble in the carrier.
  • insulin standards were prepared at 1 mg/ml in 0.01 N HCl using Sigma insulin. (One mg of this material exhibits an activity of 28 insulin units.) Stable insulin compositions samples were prepared at 1 mg/1 ml base by mixing at room temperature for 60 minutes. This mixture was then divided in half, half of which was stored at 4° C., and the other half stored at room temperature. Separation analyses, High Performance Liquid Chromatography (RP-HPLC) and High Performance Capillary Electrophoresis (HPCE), of insulin standards and insulin compositions of the invention which were stored at different temperatures for different periods of time were performed.
  • RP-HPLC High Performance Liquid Chromatography
  • HPCE High Performance Capillary Electrophoresis
  • Stable insulin compositions were formulated by first preparing a base solution.
  • Polyglycol E200 (PEG-200) (50% w/w) was weighed and polyglycol E400 (PEG-400) (5% w/w) was added to the same container to obtain the desired weight, (both obtained from Dow Corning).
  • PEG-200 and PEG-400 were lightning mixed at 38-40° C. with IKA model RW20 using a disintegration head impeller slowly at 800 rpm (speed 1), yielding PEG-200/PEG-400 solution.
  • NAT 8729 containing 80.6% PPC-enriched phosphatidylcholine and 4.9% lysophosphatidylcholine was obtained from Rhône-Poulenc.
  • NAT 8729 (45% w/w) was shaved and added to PEG-200/PEG-400 solution, covered and mixed, with temperature not exceeding 40° C., until a clear, viscous amber solution with no sediments or separations resulted. The mixing time was approximately five hours.
  • An alternative mixture can be prepared by covering and mixing the solution overnight without heat for a 95-96% yield. The solution was removed from heat and transferred to Ross Homogenizer (Model HSM100LC) using smallest mesh screen.
  • Dow Corning Fluid denominated 190 1.00% w/w
  • Dow Corning Fluid denoted 200-5 or 10 cst 1.00% w/w
  • silicone fluids containing low viscosity polydimethylsiloxane polymers were mixed together in a container with a clean spatula.
  • the solution (53.25% w/w) was warmed to 40° C. and mixed at 800 rpm. Typical mixing times were approximately 5 hours. The solution was then milled at 3800 rpm and the Dow Corning Fluid mixture was added very slowly until a clear solution resulted. Methyl Paraben (p-hydroxy benzoic acid methyl ester) obtained from Mallinckrodt (0.75% w/w) was added at once and mixed until a complete solution resulted. Purified water warmed to 40° C. was added very slowly to solution while milling at 7500 rpm for about three minutes. At end of milling, speed was increased to 10,000 rpm for few seconds before stopping. The solution was removed and swept with paddle head using IKA Model RW-20 until cooled to room temperature.
  • This step is very critical and if it is not done properly it will generate a biphasic end product.
  • the general rule is to use a container having a volume twice that of the solution so the homogenizer head is well embedded in the solution. The solution was then cooled to room temperature.
  • USP human recombinant insulin in obtained from Spectrum Chemicals and Laboratories was prepared in 0.01 N HCl at 50 mg/ml, and gently, yet well mixed. This insulin preparation was then added very slowly to the above solution to obtain a final concentration of 500 units/ml or 20 mg/ml. Mixing was continued at room temperature for at least one hour. The final stable insulin composition was stored at 4° C. in amber air-tight container.
  • Stable topical drug delivery compositions of the present invention may be employed to deliver and stabilize polypeptides transdermally, including but not limited to insulin, oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, and combinations of any of these.
  • polypeptides transdermally, including but not limited to insulin, oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, and combinations of any of these.
  • Somatotropin pituitary growth hormone
  • a drug delivery composition formulated with somatotropin was formulated in one trial with 85% phosphatidylcholine to which lipoic acid and ascorbyl palmitate were added. Somatotropin readily dispersed in phosphatidyl-choline and remained stable in it. Growth hormone appeared to penetrate the skin well when the composition was topically applied.
  • the present invention may also be used to provide topical delivery of active agents other that drugs, for example, skin care agents.
  • the invention is particularly useful with large molecules that are used in some cosmetic formulations, including peptides and polymers.

Abstract

A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.

Description

    PRIOR APPLICATION
  • This application is a continuation of U.S. patent application Ser. No. 10/749,914 filed Dec. 31, 2003, now pending, which claimed priority benefits under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Ser. No. 60/437,279 filed Dec. 31, 2002. This application is also a continuation of application Ser. No. 10/448,632 filed May 30, 2003, now pending, which claimed priority benefits under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 60/384,597, filed May 31, 2002.
  • FIELD OF THE INVENTION
  • The present invention relates to topical drug delivery compositions and methods of transdermal drug delivery. More specifically, the present invention relates to stable drug delivery compositions for topical administration.
  • BACKGROUND OF THE INVENTION
  • Topical drug delivery systems are known. These systems deliver drugs, therapeutic agents and other desired substances transdermally and may be designed to act locally at the point of application or to act systemically once entering the body's blood circulation. In these systems, delivery may be achieved by means such as direct topical application of a substance or drug in the form of an ointment or the like, or by adhesion of a patch with a reservoir or the like that holds the drug and releases it to the skin in a time-controlled fashion.
  • Transdermal delivery systems for agents such as drugs, pain relieving compounds, vitamins, and skin improving compounds have been in use for a number of years. These transdermal delivery systems using creams have been developed for use with analgesics and skin refining compounds. Transdermal systems using a patch have been developed for nicotine and estrogen therapies, for instance, estradiol technology described in U.S. Pat. No. 6,521,250 to Meconi, et al.
  • While effective for their purpose, these systems have typically only been useful for transdermal delivery of relatively small molecules. The skin's porous structure permits such small molecules to pass from the epidermis to the dermis via diffusion. However, large molecules, such as insulin, are not able to diffuse through the skin and cannot be delivered by these known means. One such solution has been provided in U.S. patent application Ser. No. 10/448,632 to Perricone, the disclosure of which is incorporated herein by reference.
  • While the delivery of large molecules such as insulin have been addressed, such systems do not address the storage and retention of the effectiveness of the drug to be delivered. Many pharmaceuticals and biologically active compounds, such as insulin, must be kept cool and away from heat to remain effective and prevent denaturing at ambient temperatures. Such substances may not be stored or carried (without refrigeration) by the user. Often drugs like insulin must be administered throughout the day and should be in ready-access to or carried by the user, which may expose the compound to high temperatures. As such, there remains a need to stabilize compositions, including insulin, so that they are resistant to warmer temperatures and have a longer life at these temperatures without a need for refrigeration
  • SUMMARY OF THE INVENTION
  • A composition for transdermal delivery of a macromolecule comprises a phosphatidylcholine carrier component entrapping the macromolecule, wherein the carrier component stabilizes the macromolecule at room temperature.
  • A method for administering a drug or other active agent comprises applying to skin composition containing an effective amount of the drug or active agent, a carrier having a phosphatidylcholine component entrapping the drug or active agent.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Phosphatidylcholine is used as a carrier for the topical delivery of polypeptides and macromolecules in the practice of this invention. Phosphatidylcholine is a basic component of cell membrane bilayers and the main phospholipid circulating in the plasma. Phosphatidylcholine is highly absorbable and supplies choline which is needed to facilitate movement of fats and oils across and maintain cell membranes in animals.
  • Topical delivery compositions of the present invention are non-polar and formulated to contain polypeptides and macromolecules soluble in phosphatidylcholine, which are then applied to skin for transdermal delivery of the macromolecule. Topical delivery compositions of the invention are efficacious in the delivery of macromolecular drugs that are conventionally administered intramuscularly, intravenously or orally, including, but not limited to polypeptides such as insulin and somatropin, prostaglandins, glucocorticoids, estrogens, androgens, and the like.
  • It is an advantage of the invention that topical administration of a composition and transdermal delivery of the drug or active agent therein is easier and pleasanter as an administration route than injections, particularly for drugs such as insulin that must be given to patients over a period of time, or for a lifetime. Furthermore, unlike oral administration where a substantial amount of the drug can be destroyed in the digestive process, the drugs in a topical application are not wasted. Topical application allows a steady diffusion of the drug to the desired target area without the cyclic dosages typical of orally or parenterally administered drugs.
  • The term “phosphatidylcholine” as used herein means a mixture of stearic, palmitic, and oleic acid diglycerides linked to the choline ester of phosphoric acid, commonly called lecithin. Many commercial lecithin products are available, such as, for example, those sold under the tradenames Lecithol®, Vitellin®, Kelecin®, and Granulestin® because lecithin is widely used in the food industry. Compositions of the invention can contain synthetic or natural lecithin, or mixtures thereof. Natural preparations are preferred because they exhibit desirable physical characteristics and are both economical and nontoxic.
  • Preferred topical delivery compositions of the present invention additionally contain polyenylphosphatidylcholine (herein abbreviated “PPC”) to enhance epidermal penetration. The term “polyenylphosphatidylcholine” as used herein means any phosphatidylcholine bearing two fatty acid substituents, wherein at least one is an unsaturated fatty acid with at least two double bonds such as linoleic acid. Certain types of soybean lecithin and soybean fractions, for example, contain higher levels of polyenylphosphatidylcholine, with dilinoleoyl-phosphatidylcholine (18:2-18:2 phosphatidylcholine) as the most abundant phosphatidylcholine species, than conventional food grade lecithin, and are useful in formulating topical delivery compositions of the invention. Alternatively, conventional soybean lecithin is enriched with polyenylphosphatidylcholine by adding soybean extracts containing high levels of polyenylphosphatidylcholine. As used herein, this type of phosphatidylcholine is called “polyenylphosphatidyl-choline-enriched” phosphatidylcholine (hereinafter referred to as PPC-enriched phosphatidylcholine), even where the term encompasses lecithin obtained from natural sources exhibiting polyenylphosphatidylcholine levels higher than ordinary soybean varieties. These products are commercially available from American Lecithin Company, Rhône-Poulenc and other lecithin vendors. American Lecithin Company markets its products with a “U” designation, indicating high levels of unsaturation; Rhône-Poulenc's product is a soybean extract containing about 42% dilinoleoylphosphatidylcholine and about 24% palmitoyllinoleylphosphatidylcholine (16:0-18:2 PC) as the major phosphatidylcholine components.
  • While not wishing to be bound to any theory, it is believed that the PPC-enriched phosphatidylcholine forms a bilayer enveloping the polypeptide or macromolecule to create the topical drug delivery composition, contributing to the stability of the active molecule and enhancing penetration. Further, the topical drug delivery composition may be in liquid crystal phase, with the PPC-enriched phosphatidylcholine loosely arranged in multilamellar fashion, with the polypeptide or macromolecule being bonded and entrapped within the lipid bilayers formed therein, as disclosed in U.S. patent application Ser. No. 10/448,632 to Perricone. This forms a loosely arranged, yet stable, PPC-enriched phosphatidylcholine-drug complex that further increases penetration and delivery of the polypeptide or macromolecule to the dermal vasculature.
  • Topical drug delivery compositions of the present invention provide an administration route that is a marked improvement over conventional insulin injections, considerably easier and pleasanter. It is a further advantage that compositions of the invention are also stable at room temperature, providing considerable convenience for insulin users who, in the past, have had to deal with the refrigerated insulin products commercially available. Also, insulin compositions according to the present invention have longer shelf lives (whether stored at room temperature or refrigerated) and will not denature at room temperature as would traditional insulin treatments.
  • Insulin useful in the topical drug delivery compositions of the present invention is commercially available from a variety of sources, marketed under the tradenames Humulin®, Novolin®, Humalog®, Inutral®, among others. Some of these products contain porcine sequences. Compositions of the invention are preferably formulated with recombinant human polypeptides such as those obtained from Sigma Co., Spectrum Chemicals and Laboratories, and similar vendors and employed in the examples that follow. It is an advantage of the invention that topical drug delivery compositions carrying insulin are formulated with commercially available ingredients.
  • Topical drug delivery compositions are generally formulated with a carrier comprising a PPC-enriched phosphatidylcholine material with the trade name NAT 8729 (commercially available from vendors such as Rhône-Poulenc and American Lecithin Company) and at least one polyglycol (polyhydric alcohol of a monomeric glycol such as polyethylene glycol (PEG) having molecular weights of 200, 300, 400, 600, 1000, 1450, 3350, 4000, 6000, 8000 and 20000. Further, this carrier may comprise a surfactant such as a siloxylated polyether comprising dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane or silicone glycol copolymer fluid commercially available from vendors such as Dow Corning, e.g. poly(oxyehtylene.oxypropylene) methyl polysiloxanne copolymer sold under the tradename Dow Corning 190 surfactant, and lubricant such as silicone fluids containing low viscosity polydimethylsiloxane polymers, methylparaben (p-hydroxy benzoic acid methyl ester) commercially available from vendors such as Down Corning (under the tradename Dow Corning 200 silicone fluid). Additionally, purified water may be added to the carrier. The carrier is then mixed with a preparation of the particular polypeptide(s) or macromolecule(s) in an amount to obtain the desired strength in the final composition. The following examples are presented to further illustrate and explain the present invention and should not be taken as limiting in any regard.
  • EXAMPLE 1 Preparation of Stable Insulin Compositions
  • Stable insulin topical preparations were formulated by first preparing a base solution. A polyenylphosphatidylcholine material denoted NAT 8729 which contained 80.6% PPC-enriched phosphatidylcholine and 4.9% lysophosphatidylcholine was obtained from Rhône-Poulenc. NAT 8729 (45% w/w) was shaved and added to a mixture of polyglycol E200 (50% w/w) and polyglycol E400 (5% w/w) both obtained from Dow Corning. The base solution was then covered well and lightning mixed with a special disintegration head impeller slowly at 800 rpm with slight heat. The temperature did not go above 40° C. Typical mixing times were 5 hours. The final solution is a crystal clear, viscous amber solution with no sediments or separations.
  • Into this base solution (97.25% w/w) was then mixed a Dow Corning Fluid 190 (1.00% w/w) [a siloxylated polyether comprising dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane]; a Dow Corning silicone fluid denoted 200-5 or 10cst (1.00% w/w) [silicone fluids containing low viscosity polydimethylsiloxane polymers]; and methylparaben [p-hydroxy benzoic acid methyl ester] obtained from vendor Mallinckrodt (0.75% w/w). The ingredients were homogenized with 3850 rpm with a 0.45 micron screen as follows. The methylparaben was first added to the base solution and mixed for at least an hour until a complete solution formed. Then the Dow Corning 200-5 or 10 cst was slowly added and mixed until a clear solution formed. Afterwards the Dow Corning Fluid 190 was added slowly and mixed into the solution to form the carrier.
  • Insulin preparations of the invention were then made using the carrier in two strengths: 50 units and 100 units, by simply dissolving RNA-derived recombinant human insulin obtained from Sigma into the carrier. It was readily soluble in the carrier.
  • In testing the stability of the stable insulin composition, insulin standards were prepared at 1 mg/ml in 0.01 N HCl using Sigma insulin. (One mg of this material exhibits an activity of 28 insulin units.) Stable insulin compositions samples were prepared at 1 mg/1 ml base by mixing at room temperature for 60 minutes. This mixture was then divided in half, half of which was stored at 4° C., and the other half stored at room temperature. Separation analyses, High Performance Liquid Chromatography (RP-HPLC) and High Performance Capillary Electrophoresis (HPCE), of insulin standards and insulin compositions of the invention which were stored at different temperatures for different periods of time were performed.
  • The RP-HPLC and HPCE analyses indicated that insulin standards that were stored at 4° C. or −20° C. were stable after 65 days, but insulin standards stored at room temperature started to denature within 7 days. The RP-HPLC and HPCE profiles of insulin compositions of the invention, on the other hand, were stable at both room temperature and at 4° C., and did not change after 65 days. The results clearly showed that the carrier prevented the denaturing of the insulin stored at room temperature.
  • EXAMPLE 2 Preparation of Stable Insulin Compositions
  • Stable insulin compositions were formulated by first preparing a base solution. Polyglycol E200 (PEG-200) (50% w/w) was weighed and polyglycol E400 (PEG-400) (5% w/w) was added to the same container to obtain the desired weight, (both obtained from Dow Corning). PEG-200 and PEG-400 were lightning mixed at 38-40° C. with IKA model RW20 using a disintegration head impeller slowly at 800 rpm (speed 1), yielding PEG-200/PEG-400 solution. A PPC-enriched phosphatidylcholine material denoted NAT 8729 containing 80.6% PPC-enriched phosphatidylcholine and 4.9% lysophosphatidylcholine was obtained from Rhône-Poulenc. NAT 8729 (45% w/w) was shaved and added to PEG-200/PEG-400 solution, covered and mixed, with temperature not exceeding 40° C., until a clear, viscous amber solution with no sediments or separations resulted. The mixing time was approximately five hours. An alternative mixture can be prepared by covering and mixing the solution overnight without heat for a 95-96% yield. The solution was removed from heat and transferred to Ross Homogenizer (Model HSM100LC) using smallest mesh screen.
  • A Dow Corning Fluid was then prepared. Dow Corning Fluid denominated 190 (1.00% w/w) [a siloxylated polyether comprising dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane] and Dow Corning Fluid denoted 200-5 or 10 cst (1.00% w/w) [silicone fluids containing low viscosity polydimethylsiloxane polymers] were mixed together in a container with a clean spatula.
  • The solution (53.25% w/w) was warmed to 40° C. and mixed at 800 rpm. Typical mixing times were approximately 5 hours. The solution was then milled at 3800 rpm and the Dow Corning Fluid mixture was added very slowly until a clear solution resulted. Methyl Paraben (p-hydroxy benzoic acid methyl ester) obtained from Mallinckrodt (0.75% w/w) was added at once and mixed until a complete solution resulted. Purified water warmed to 40° C. was added very slowly to solution while milling at 7500 rpm for about three minutes. At end of milling, speed was increased to 10,000 rpm for few seconds before stopping. The solution was removed and swept with paddle head using IKA Model RW-20 until cooled to room temperature. This step is very critical and if it is not done properly it will generate a biphasic end product. The general rule is to use a container having a volume twice that of the solution so the homogenizer head is well embedded in the solution. The solution was then cooled to room temperature.
  • USP human recombinant insulin in obtained from Spectrum Chemicals and Laboratories (Product #11247) was prepared in 0.01 N HCl at 50 mg/ml, and gently, yet well mixed. This insulin preparation was then added very slowly to the above solution to obtain a final concentration of 500 units/ml or 20 mg/ml. Mixing was continued at room temperature for at least one hour. The final stable insulin composition was stored at 4° C. in amber air-tight container.
  • RP-HPLC and HPCE analyses of insulin standards (prepared at 5 mg/ml in 0.01 N HCl) and stable insulin compositions of the invention which were stored at different temperatures for different periods of time were performed. The results indicated that standard insulin standards stored at 4° were stable up to 22 weeks and started to denature after 34 weeks, whereas when stored at room temperature started to denature within only 1 week. However, the stable insulin compositions prepared in accordance with the above disclosures that were stored at room temperature were stable up to at least 22 weeks, which is 21 weeks longer than the standard. The results showed no change in shelf-life from the standard for stable insulin compositions stored at 4° C. (no change after 34 weeks).
  • Stable topical drug delivery compositions of the present invention may be employed to deliver and stabilize polypeptides transdermally, including but not limited to insulin, oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, and combinations of any of these. These drugs are readily available from a variety of commercial sources. Somatotropin (pituitary growth hormone) is marketed under the tradenames Gentropin®, Humatrope®, Nutropin®, and Serostim®.
  • A drug delivery composition formulated with somatotropin was formulated in one trial with 85% phosphatidylcholine to which lipoic acid and ascorbyl palmitate were added. Somatotropin readily dispersed in phosphatidyl-choline and remained stable in it. Growth hormone appeared to penetrate the skin well when the composition was topically applied.
  • The present invention may also be used to provide topical delivery of active agents other that drugs, for example, skin care agents. The invention is particularly useful with large molecules that are used in some cosmetic formulations, including peptides and polymers.
  • The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it is not intended to detail all those obvious modifications and variations of it which will become apparent to the skilled worker upon reading the description. It is intended, however, that all such obvious modifications and variations be included within the scope of the present invention

Claims (14)

1. A carrier composition for transdermal delivery of a macromolecule, comprising a polyenylphosphatidylcholine-enriched phosphatidylcholine and polyglycol mixture entrapping said macromolecule for transdermal delivery to dermal vasculature, wherein said phosphatidylcholine component stabilizes said macromolecule at room temperature.
2. The composition of claim 1, wherein said phosphatidylcholine and polyglycol mixture comprises two or more polyglycols.
3. The composition of claim 2, wherein at least one polyglycol is polyglycol having a molecular weight of 200 and another polyglycol is polyglycol having a molecular weight of 400.
4. The composition of claim 3, wherein said phosphatidylcholine and polyglycol mixture comprises 45% w/w polyenylphosphatidylcholine-enriched phosphatidylcholine, 50% w/w polyglycol having molecular weight of 200, and 5% w/w having molecular weight of 400.
5. The composition of claim 1, further comprising a surfactant, a lubricant, and methyl paraben.
6. The composition of claim 5, comprising 97.25% w/w phosphatidylcholine and polyglycol mixture, 1.00% w/w surfactant, 1.00% w/w lubricant, and 0.75% w/w methyl paraben.
7. The composition of claim 5, further comprising water.
8. The composition of claim 7, comprising 53.25% w/w phosphatidylcholine and polyglycol mixture, 1.00% w/w surfactant, 1.00% w/w lubricant, 0.75% w/w methyl paraben and 44% w/w water.
9. The composition of claim 5, wherein said surfactant is a siloxylated polyether.
10. The composition of claim 9, wherein said siloxylated polyether is dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane.
11. The composition of claim 5, wherein said lubricant is silicone fluid.
12. The composition of claim 11, wherein said silicone fluid contains low viscosity polydimethylsiloxane polymers.
13. The composition of claim 1, wherein said macromolecule is selected from the group consisting of oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, peptides, polymers, and combinations of any of these.
14. The composition of claim 1, wherein said macromolecule comprises insulin entrapped within said carrier for transdermal delivery of the insulin to dermal vasculature.
US11/506,137 2002-05-31 2006-08-17 Stable topical drug delivery compositions Abandoned US20060275353A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/506,137 US20060275353A1 (en) 2002-05-31 2006-08-17 Stable topical drug delivery compositions
US12/796,213 US20100311696A1 (en) 2002-05-31 2010-06-08 Topical skin treatment composition

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38459702P 2002-05-31 2002-05-31
US43727902P 2002-12-31 2002-12-31
US10/448,632 US20040018237A1 (en) 2002-05-31 2003-05-30 Topical drug delivery using phosphatidylcholine
US10/749,914 US7182956B2 (en) 2002-05-31 2003-12-31 Stable topical drug delivery compositions
US11/506,137 US20060275353A1 (en) 2002-05-31 2006-08-17 Stable topical drug delivery compositions

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/448,632 Continuation US20040018237A1 (en) 2002-05-31 2003-05-30 Topical drug delivery using phosphatidylcholine
US10/749,914 Continuation US7182956B2 (en) 2002-05-31 2003-12-31 Stable topical drug delivery compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/796,213 Continuation-In-Part US20100311696A1 (en) 2002-05-31 2010-06-08 Topical skin treatment composition

Publications (1)

Publication Number Publication Date
US20060275353A1 true US20060275353A1 (en) 2006-12-07

Family

ID=29715338

Family Applications (14)

Application Number Title Priority Date Filing Date
US10/448,632 Abandoned US20040018237A1 (en) 2002-05-31 2003-05-30 Topical drug delivery using phosphatidylcholine
US10/749,914 Expired - Fee Related US7182956B2 (en) 2002-05-31 2003-12-31 Stable topical drug delivery compositions
US11/334,206 Abandoned US20060105955A1 (en) 2002-05-31 2006-01-18 Topical drug delivery using phosphatidylcholine
US11/344,442 Abandoned US20060127469A1 (en) 2002-05-31 2006-01-31 Methods of delivering stable topical drug compositions
US11/506,137 Abandoned US20060275353A1 (en) 2002-05-31 2006-08-17 Stable topical drug delivery compositions
US12/830,857 Abandoned US20100292139A1 (en) 2002-05-31 2010-07-06 Topical drug delivery using phosphatidylcholine
US13/019,101 Abandoned US20110123577A1 (en) 2002-05-31 2011-02-01 Method Of Delivering Stable Topical Drug Compositions
US13/024,689 Expired - Lifetime US8273711B2 (en) 2002-05-31 2011-02-10 Topical drug delivery using phosphatidylcholine
US13/926,688 Abandoned US20130330380A1 (en) 2002-05-31 2013-06-25 Topical drug delivery using phosphatidylcholine
US13/947,353 Expired - Fee Related US9050248B2 (en) 2002-05-31 2013-07-22 Methods of delivering stable topical drug compositions
US13/947,329 Expired - Fee Related US9060925B2 (en) 2002-05-31 2013-07-22 Methods of delivering stable topical drug compositions
US13/947,389 Abandoned US20130330381A1 (en) 2002-05-31 2013-07-22 Methods of delivering stable topical drug compositions
US14/296,634 Abandoned US20150004196A1 (en) 2002-05-31 2014-06-05 Topical drug delivery using phosphatidylcholine
US14/705,023 Abandoned US20150238608A1 (en) 2002-05-31 2015-05-06 Methods of delivering stable topical drug compositions

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US10/448,632 Abandoned US20040018237A1 (en) 2002-05-31 2003-05-30 Topical drug delivery using phosphatidylcholine
US10/749,914 Expired - Fee Related US7182956B2 (en) 2002-05-31 2003-12-31 Stable topical drug delivery compositions
US11/334,206 Abandoned US20060105955A1 (en) 2002-05-31 2006-01-18 Topical drug delivery using phosphatidylcholine
US11/344,442 Abandoned US20060127469A1 (en) 2002-05-31 2006-01-31 Methods of delivering stable topical drug compositions

Family Applications After (9)

Application Number Title Priority Date Filing Date
US12/830,857 Abandoned US20100292139A1 (en) 2002-05-31 2010-07-06 Topical drug delivery using phosphatidylcholine
US13/019,101 Abandoned US20110123577A1 (en) 2002-05-31 2011-02-01 Method Of Delivering Stable Topical Drug Compositions
US13/024,689 Expired - Lifetime US8273711B2 (en) 2002-05-31 2011-02-10 Topical drug delivery using phosphatidylcholine
US13/926,688 Abandoned US20130330380A1 (en) 2002-05-31 2013-06-25 Topical drug delivery using phosphatidylcholine
US13/947,353 Expired - Fee Related US9050248B2 (en) 2002-05-31 2013-07-22 Methods of delivering stable topical drug compositions
US13/947,329 Expired - Fee Related US9060925B2 (en) 2002-05-31 2013-07-22 Methods of delivering stable topical drug compositions
US13/947,389 Abandoned US20130330381A1 (en) 2002-05-31 2013-07-22 Methods of delivering stable topical drug compositions
US14/296,634 Abandoned US20150004196A1 (en) 2002-05-31 2014-06-05 Topical drug delivery using phosphatidylcholine
US14/705,023 Abandoned US20150238608A1 (en) 2002-05-31 2015-05-06 Methods of delivering stable topical drug compositions

Country Status (10)

Country Link
US (14) US20040018237A1 (en)
EP (1) EP1509243B1 (en)
JP (1) JP2005531595A (en)
CN (1) CN100509054C (en)
AU (1) AU2003231943B2 (en)
CA (1) CA2487305A1 (en)
ES (1) ES2632912T3 (en)
HK (1) HK1083009A1 (en)
IL (2) IL165480A0 (en)
WO (1) WO2003101480A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123577A1 (en) * 2002-05-31 2011-05-26 Perricone Nicholas V Method Of Delivering Stable Topical Drug Compositions
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20070148224A1 (en) * 2005-12-28 2007-06-28 Discovery Partners Llc Skin treatment compositions containing copper-pigment complexes
US20070148222A1 (en) * 2005-12-28 2007-06-28 Discovery Partners Llc Skin treatment compositions containing copper-pigment complexes
WO2008032227A2 (en) * 2006-09-11 2008-03-20 Biomas, Ltd. Topical formulations of tellurium-containing compounds
US20080317836A1 (en) * 2007-06-19 2008-12-25 Discovery Partners Llc Topical compositions for anti-aging skin treatment
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068256A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
FR2950807B1 (en) * 2009-10-06 2012-02-03 Lvmh Rech COSMETIC COMPOSITION CONTAINING LIPOSOMES ENCAPSULATED IN OXAZOLIDIN-2-ONE COMPOUND
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (en) 2010-03-30 2015-11-10 フォスファジェニクス リミティド Transdermal delivery patch
WO2011152832A1 (en) 2010-06-04 2011-12-08 N.V. Perricone Llc Methods of use of nitroalkene compositions in dermatologic applications to prevent or treat skin aging
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
US8986739B2 (en) * 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
KR101943508B1 (en) 2011-07-21 2019-01-30 (주)아모레퍼시픽 Cosmetic compositions having relaxing effect of fatigued muscle
US20160136169A1 (en) * 2012-09-19 2016-05-19 Transdermal Biotechnology, Inc. Systems and methods for delivery of tetrahydrobiopterin and related compounds
US20140271742A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN106413711A (en) 2014-04-02 2017-02-15 艾伯维公司 Methods for treating HCV
US9707266B2 (en) 2014-11-18 2017-07-18 Transdermal Biotechnology, Inc. Methods and systems for delivery of ZW1 heptapeptide
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN114712308A (en) 2015-12-09 2022-07-08 磷肌酸有限公司 Pharmaceutical preparation
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
US9949939B2 (en) 2016-07-01 2018-04-24 Transdermal Biotechnology, Inc. Systems and methods for treating vitiligo
CN110662733A (en) 2016-12-21 2020-01-07 埃维科生物技术有限公司 Method of producing a composite material
JP6940889B2 (en) * 2018-01-31 2021-09-29 株式会社ユニッシュ Phosphatidylcholine transdermal preparation
WO2022192135A1 (en) * 2021-03-08 2022-09-15 Transdermal Biotechnology, Inc. Dendrimer-n-actyl-l-cysteine conjugates for treatment or prevention of aging skin or other indications
WO2022221376A1 (en) 2021-04-14 2022-10-20 Transdermal Biotechnology, Inc. Systems and methods for treating vitiligo using ethyl pyruvate and other compounds

Citations (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US482554A (en) * 1892-09-13 Joseph galland
US561330A (en) * 1896-06-02 ljungstrom
US722323A (en) * 1900-03-26 1903-03-10 Benjamin W Parker Letter-box.
US727323A (en) * 1901-10-04 1903-05-05 Harry Feder Dress-stay blank.
US2181390A (en) * 1933-08-09 1939-11-28 Arthur M Barrett Easel
US2182390A (en) * 1937-01-13 1939-12-05 William F Reardon Surgical device
US4174296A (en) * 1978-12-04 1979-11-13 American Lecithin Company Water soluble lecithin composition
US4333927A (en) * 1980-03-27 1982-06-08 Mitsubishi Chemical Industries, Ltd. Skin preparation
US4614730A (en) * 1981-10-30 1986-09-30 Novo Industri A/S Stabilized insulin preparations and a process for preparation thereof
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4687661A (en) * 1983-06-29 1987-08-18 Daiichi Seiyaku Co., Ltd. Method for producing liposomes
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4743449A (en) * 1983-09-12 1988-05-10 Fujisawa Pharmaceutical Co., Ltd. Drug-containing lipid vesicle preparation and method for preparing them
US5120561A (en) * 1991-04-25 1992-06-09 American Lecithin Company Food composition and method
US5151272A (en) * 1982-11-26 1992-09-29 Fluid-Carbon International Ab Method of preparing controlled-release preparations for biologically active materials and resulting compositions
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5254348A (en) * 1990-01-26 1993-10-19 Lts Lohmann Therapie Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising tulobuterol as active substance
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5380761A (en) * 1991-04-15 1995-01-10 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Transdermal compositions
US5391548A (en) * 1986-10-31 1995-02-21 Pfizer Inc. Transdermal flux enhancing compositions to treat hypertension, diabetes and angina pectoris
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
US5476651A (en) * 1991-05-22 1995-12-19 Lvmh Recherche Cosmetic or pharmaceutical composition, especially dermatological composition, intended for promoting the pigmentation of the skin or hair, containing an extract of cyperus, and the process for its manufacture
US5484816A (en) * 1992-07-13 1996-01-16 Shiseido Company, Ltd. External skin treatment composition
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
US5550263A (en) * 1991-06-03 1996-08-27 Karlshamns Lipidteknik Ab X-ray contrast agent
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5693676A (en) * 1994-05-27 1997-12-02 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
US5726164A (en) * 1995-03-21 1998-03-10 Novartis Corporation Nanosuspensions for intravenous administration
US5776494A (en) * 1996-12-20 1998-07-07 The Procter & Gamble Company Pharmaceuticals compositions containing gellants in the form of alkyl amides of di-and tri-carboxylic acids
US5807573A (en) * 1994-06-15 1998-09-15 Gs Development Ab Lipid based composition containing diacylglycerol, phospholipid, polar liquid and biologically active material
US5814666A (en) * 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US5955502A (en) * 1994-03-30 1999-09-21 Gs Development Ab Use of fatty acid esters as bioadhesive substances
US5976562A (en) * 1994-02-01 1999-11-02 Krall; Theodor Process for producing bactericidal/fungicidal plastic bodies
WO1999056725A1 (en) * 1998-04-30 1999-11-11 Ucb, S.A. Pharmaceutical compositions capable of being gelled
US5985298A (en) * 1994-10-25 1999-11-16 Revlon Consumer Products Corporation Cosmetic compositions
US6022561A (en) * 1994-02-04 2000-02-08 Scotia Lipidteknik Ab Bilayers preparations
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6133320A (en) * 1996-03-19 2000-10-17 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6211250B1 (en) * 1996-11-22 2001-04-03 Soltec Research Pty Ltd. Percutaneous delivery system
US6214375B1 (en) * 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6242099B1 (en) * 1996-11-21 2001-06-05 Merck S.A. Microcapsules made of chitin or of chitin derivatives containing a hydrophobic substance, in particular a sunscreen, and process for the preparation of such microcapsules
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6391869B1 (en) * 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20020131994A1 (en) * 2001-01-10 2002-09-19 Schur Henry B. Non-irritating formulation for the transdermal delivery of substances
US20020153509A1 (en) * 2001-02-21 2002-10-24 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20020160040A1 (en) * 2001-02-20 2002-10-31 Spicer Patrick Thomas Cubic liquid crystalline compositions and methods for their preparation
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
US6521250B2 (en) * 1993-05-06 2003-02-18 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system containing estradiol
US6538061B2 (en) * 2001-05-16 2003-03-25 General Electric Company Cosmetic compositions using polyether siloxane copolymer network compositions
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20040096494A1 (en) * 2001-03-15 2004-05-20 Britta Siekmann Composition
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20040191305A1 (en) * 2002-05-31 2004-09-30 Perricone Nicholas V. Methods for formulating stabilized insulin compositions
US6858398B2 (en) * 2001-08-14 2005-02-22 Immunosciences Lab., Inc. Saliva test for detection of food allergy and intolerance
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
US20050226945A1 (en) * 2004-04-13 2005-10-13 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
US7033574B1 (en) * 1990-04-02 2006-04-25 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US20090214624A1 (en) * 2004-11-29 2009-08-27 The University Of Akron Topical nitric oxide donor devices and methods for their therapeutic use
US20090304815A1 (en) * 2006-02-03 2009-12-10 Giulio Cossu Method of treatment for muscular dystrophy
US20090324698A1 (en) * 2004-10-18 2009-12-31 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle, the production of this composition and the therapeutic use thereof
US20100048520A1 (en) * 2006-03-09 2010-02-25 Salix Pharmaceuticals, Ltd. Rifaximin anti-rectal dysfunction preparation
US7820420B2 (en) * 2000-08-11 2010-10-26 Whitlock David R Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US20100311696A1 (en) * 2002-05-31 2010-12-09 Perricone Nicholas V Topical skin treatment composition
US20110104240A1 (en) * 2008-06-24 2011-05-05 Micropharma Limited Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections
US7976743B2 (en) * 2006-10-16 2011-07-12 Northwestern University Gas-containing liposomes
US20120156163A1 (en) * 2010-12-15 2012-06-21 Susanne Bauman Methods of decreasing sebum production in the skin
US20130029989A1 (en) * 2010-04-15 2013-01-31 The Royal Institution For The Advancement Of Learning/Mcgill University Topical treatments for pain

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251861A (en) * 1978-10-27 1981-02-17 Mago Gyula A Cellular network of processors
GB2134869A (en) * 1983-02-15 1984-08-22 Squibb & Sons Inc Method of preparing liposomes and products produced thereby
JPS60155109A (en) * 1984-01-23 1985-08-15 Terumo Corp Liposome pharmaceutical
JPS6176414A (en) * 1984-09-21 1986-04-18 Shionogi & Co Ltd Production of liposome preparation
US4657661A (en) * 1985-12-11 1987-04-14 Chevron Research Company Process for improving the storage stability and bulk oxidation stability of lube base stocks derived from bright stock
EP0256119A4 (en) 1986-02-10 1988-08-23 Liposome Technology Inc Controlled-release liposome delivery system.
US4833468A (en) * 1987-10-14 1989-05-23 Unisys Corporation Layered network
US5223476A (en) 1989-05-02 1993-06-29 Dai Nippon Insatsu Kabushiki Kaisha Heat transfer sheet
JP3765579B2 (en) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー Ultra-fine droplet preparation for active substance administration
CA2053462A1 (en) 1990-10-22 1992-04-23 Yoshiaki Yano Sticky composition for medical use
ES2133391T3 (en) * 1991-10-04 1999-09-16 Gs Dev Ab PARTICLES, METHOD FOR PREPARING SUCH PARTICLES AND USES OF THE SAME.
DE4208552A1 (en) 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh TOPICAL MEDICINE FORMS WITH INSULIN
US5555405A (en) * 1993-07-06 1996-09-10 Digital Equipment Corporation Method and apparatus for free space management in a forwarding database having forwarding entry sets and multiple free space segment queues
AU679553B2 (en) * 1993-07-07 1997-07-03 European Computer-Industry Research Centre Gmbh Database structures
FI100692B (en) * 1994-05-24 1998-02-13 Leiras Oy A process for the preparation of pharmaceutical compositions, wherein the compositions are based on microemulsion gels and new gels directed to microemulsions.
US5787430A (en) * 1994-06-30 1998-07-28 International Business Machines Corporation Variable length data sequence backtracking a trie structure
WO1996003991A1 (en) 1994-08-05 1996-02-15 Inpharma S.A. Compositions containing prostaglandin e1 and/or troxerutine complexed with phosphatidylcholine for topical treatment of erectile impotence
US5761440A (en) * 1994-09-15 1998-06-02 International Business Machines Corporation System and method utilizing multiple search trees to route data within a data processing network
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
CA2181390C (en) 1995-07-18 2001-04-24 Pankaj Modi Phospholipid formulations
DE19640092A1 (en) 1996-09-28 1998-04-16 Beiersdorf Ag Structures with lipid double membranes, in the lipophilic area of which longer-chain molecules are immersed or which are docked to such molecules through hydrophobic interactions
US5909440A (en) * 1996-12-16 1999-06-01 Juniper Networks High speed variable length best match look-up in a switching device
JPH10194994A (en) 1997-01-16 1998-07-28 Pola Chem Ind Inc Absorption acceleration composition
US6021131A (en) * 1997-07-08 2000-02-01 Lucent Technologies, Inc. Sorting networks having enhanced layout
JPH1179975A (en) 1997-09-05 1999-03-23 Mitsui Chem Inc Preparation of microcapsule
US6018524A (en) * 1997-09-09 2000-01-25 Washington University Scalable high speed IP routing lookups
US6266706B1 (en) * 1997-09-15 2001-07-24 Effnet Group Ab Fast routing lookup system using complete prefix tree, bit vector, and pointers in a routing table for determining where to route IP datagrams
US6041053A (en) * 1997-09-18 2000-03-21 Microsfot Corporation Technique for efficiently classifying packets using a trie-indexed hierarchy forest that accommodates wildcards
US6563823B1 (en) * 1997-10-30 2003-05-13 Marconi Communications, Inc. Multi-resolution tree for longest match address lookups
US6061712A (en) * 1998-01-07 2000-05-09 Lucent Technologies, Inc. Method for IP routing table look-up
US6289013B1 (en) * 1998-02-09 2001-09-11 Lucent Technologies, Inc. Packet filter method and apparatus employing reduced memory
US6341130B1 (en) * 1998-02-09 2002-01-22 Lucent Technologies, Inc. Packet classification method and apparatus employing two fields
US6092072A (en) * 1998-04-07 2000-07-18 Lucent Technologies, Inc. Programmed medium for clustering large databases
US6522632B1 (en) * 1998-05-06 2003-02-18 Avici Systems Apparatus and method for efficient prefix search
US6157955A (en) * 1998-06-15 2000-12-05 Intel Corporation Packet processing system including a policy engine having a classification unit
AU4848499A (en) * 1998-07-08 2000-02-01 Broadcom Corporation Network switch utilizing packet based per head-of-line blocking prevention
US6212184B1 (en) * 1998-07-15 2001-04-03 Washington University Fast scaleable methods and devices for layer four switching
JP2000086501A (en) 1998-09-11 2000-03-28 Sankyo Co Ltd Liposome formulation of human calcitonin
MXPA02000053A (en) 1999-07-05 2003-07-21 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers.
JP2003520210A (en) 2000-01-05 2003-07-02 イマレックス セラピューティクス, インコーポレイテッド Pharmaceutical formulations for delivery of drugs with low water solubility
US6581106B1 (en) * 2000-01-13 2003-06-17 Pierluigi Crescenzi Fast address lookup in routing tables
ATE319249T1 (en) * 2000-01-27 2006-03-15 Ibm METHOD AND DEVICE FOR CLASSIFICATION OF DATA PACKETS
BR0005797A (en) * 2000-03-20 2001-10-16 Abbott Lab Methods for the treatment of sexual dysfunction with apomorphine at specified plasma concentration levels
KR20020066778A (en) 2001-02-13 2002-08-21 한국과학기술연구원 Formulation to enhance bioavailability of bioactive materials and preparation method thereof
KR100508695B1 (en) 2001-02-13 2005-08-17 한국과학기술연구원 Formulation for oral delivery of insulin and preparation method thereof
US6568061B2 (en) * 2001-09-21 2003-05-27 Atlantic Research Corporation Method for controlling composite preform elements during processing
CN100551345C (en) 2002-12-31 2009-10-21 特兰斯德梅尔生物工艺股份有限公司 Stable localized drug delivery compositions
CA2830298C (en) * 2011-03-17 2016-08-16 Transdermal Biotechnology, Inc. Topical nitric oxide systems comprising lecithin and methods of use thereof
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271742A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US482554A (en) * 1892-09-13 Joseph galland
US561330A (en) * 1896-06-02 ljungstrom
US722323A (en) * 1900-03-26 1903-03-10 Benjamin W Parker Letter-box.
US727323A (en) * 1901-10-04 1903-05-05 Harry Feder Dress-stay blank.
US2181390A (en) * 1933-08-09 1939-11-28 Arthur M Barrett Easel
US2182390A (en) * 1937-01-13 1939-12-05 William F Reardon Surgical device
US4174296A (en) * 1978-12-04 1979-11-13 American Lecithin Company Water soluble lecithin composition
US4333927A (en) * 1980-03-27 1982-06-08 Mitsubishi Chemical Industries, Ltd. Skin preparation
US4614730A (en) * 1981-10-30 1986-09-30 Novo Industri A/S Stabilized insulin preparations and a process for preparation thereof
US5753259A (en) * 1982-11-26 1998-05-19 Gs Development Ab Method of preparing controlled-release preparations for biologically active materials and resulting compositions
US5151272A (en) * 1982-11-26 1992-09-29 Fluid-Carbon International Ab Method of preparing controlled-release preparations for biologically active materials and resulting compositions
US4687661A (en) * 1983-06-29 1987-08-18 Daiichi Seiyaku Co., Ltd. Method for producing liposomes
US4743449A (en) * 1983-09-12 1988-05-10 Fujisawa Pharmaceutical Co., Ltd. Drug-containing lipid vesicle preparation and method for preparing them
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5391548A (en) * 1986-10-31 1995-02-21 Pfizer Inc. Transdermal flux enhancing compositions to treat hypertension, diabetes and angina pectoris
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5254348A (en) * 1990-01-26 1993-10-19 Lts Lohmann Therapie Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising tulobuterol as active substance
US7033574B1 (en) * 1990-04-02 2006-04-25 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5380761A (en) * 1991-04-15 1995-01-10 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Transdermal compositions
US5120561A (en) * 1991-04-25 1992-06-09 American Lecithin Company Food composition and method
US5476651A (en) * 1991-05-22 1995-12-19 Lvmh Recherche Cosmetic or pharmaceutical composition, especially dermatological composition, intended for promoting the pigmentation of the skin or hair, containing an extract of cyperus, and the process for its manufacture
US5550263A (en) * 1991-06-03 1996-08-27 Karlshamns Lipidteknik Ab X-ray contrast agent
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5814666A (en) * 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5484816A (en) * 1992-07-13 1996-01-16 Shiseido Company, Ltd. External skin treatment composition
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US6521250B2 (en) * 1993-05-06 2003-02-18 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system containing estradiol
US5662932A (en) * 1993-05-18 1997-09-02 Pharmos Corporation Solid fat nanoemulsions
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US5976562A (en) * 1994-02-01 1999-11-02 Krall; Theodor Process for producing bactericidal/fungicidal plastic bodies
US6022561A (en) * 1994-02-04 2000-02-08 Scotia Lipidteknik Ab Bilayers preparations
US5955502A (en) * 1994-03-30 1999-09-21 Gs Development Ab Use of fatty acid esters as bioadhesive substances
US5693676A (en) * 1994-05-27 1997-12-02 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
US7189761B2 (en) * 1994-05-27 2007-03-13 Gorfine Stephen R Nitric oxide donor composition and method for treatment of anal disorders
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
US5807573A (en) * 1994-06-15 1998-09-15 Gs Development Ab Lipid based composition containing diacylglycerol, phospholipid, polar liquid and biologically active material
US5985298A (en) * 1994-10-25 1999-11-16 Revlon Consumer Products Corporation Cosmetic compositions
US5726164A (en) * 1995-03-21 1998-03-10 Novartis Corporation Nanosuspensions for intravenous administration
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US6133320A (en) * 1996-03-19 2000-10-17 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6214375B1 (en) * 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US6045827A (en) * 1996-11-19 2000-04-04 Meri Charmyne Russell Treatment of equine laminitis
US6287601B1 (en) * 1996-11-19 2001-09-11 Meri Charmyne Russell Topical nitric oxide donor compositions
US6242099B1 (en) * 1996-11-21 2001-06-05 Merck S.A. Microcapsules made of chitin or of chitin derivatives containing a hydrophobic substance, in particular a sunscreen, and process for the preparation of such microcapsules
US6211250B1 (en) * 1996-11-22 2001-04-03 Soltec Research Pty Ltd. Percutaneous delivery system
US5776494A (en) * 1996-12-20 1998-07-07 The Procter & Gamble Company Pharmaceuticals compositions containing gellants in the form of alkyl amides of di-and tri-carboxylic acids
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6458841B2 (en) * 1997-09-17 2002-10-01 New England Property Holdings, Llc Topical and oral delivery of arginine to cause beneficial effects
WO1999056725A1 (en) * 1998-04-30 1999-11-11 Ucb, S.A. Pharmaceutical compositions capable of being gelled
US6464987B1 (en) * 1998-04-30 2002-10-15 Ucb, S.A. Pharmaceutical compositions capable of being gelled
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
US6391869B1 (en) * 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
US7820420B2 (en) * 2000-08-11 2010-10-26 Whitlock David R Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US7696247B2 (en) * 2000-12-21 2010-04-13 Boston Scientific Scimed, Inc. Lipid-based nitric oxide donors
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20020131994A1 (en) * 2001-01-10 2002-09-19 Schur Henry B. Non-irritating formulation for the transdermal delivery of substances
US20020160040A1 (en) * 2001-02-20 2002-10-31 Spicer Patrick Thomas Cubic liquid crystalline compositions and methods for their preparation
US20020153509A1 (en) * 2001-02-21 2002-10-24 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20040096494A1 (en) * 2001-03-15 2004-05-20 Britta Siekmann Composition
US6538061B2 (en) * 2001-05-16 2003-03-25 General Electric Company Cosmetic compositions using polyether siloxane copolymer network compositions
US6858398B2 (en) * 2001-08-14 2005-02-22 Immunosciences Lab., Inc. Saliva test for detection of food allergy and intolerance
US20060127469A1 (en) * 2002-05-31 2006-06-15 Perricone Nicholas V Methods of delivering stable topical drug compositions
US20130330381A1 (en) * 2002-05-31 2013-12-12 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US20060105955A1 (en) * 2002-05-31 2006-05-18 Perricone Nicholas V Topical drug delivery using phosphatidylcholine
US20040197391A1 (en) * 2002-05-31 2004-10-07 Perricone Nicholas V. Stable topical drug delivery compositions
US7182956B2 (en) * 2002-05-31 2007-02-27 Nicholas V. Perricone Stable topical drug delivery compositions
US20040191305A1 (en) * 2002-05-31 2004-09-30 Perricone Nicholas V. Methods for formulating stabilized insulin compositions
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20130330380A1 (en) * 2002-05-31 2013-12-12 Transdermal Biotechnology, Inc. Topical drug delivery using phosphatidylcholine
US20110123577A1 (en) * 2002-05-31 2011-05-26 Perricone Nicholas V Method Of Delivering Stable Topical Drug Compositions
US8273711B2 (en) * 2002-05-31 2012-09-25 Transdermal Biotechnology, Inc. Topical drug delivery using phosphatidylcholine
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20130331318A1 (en) * 2002-05-31 2013-12-12 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US20100292139A1 (en) * 2002-05-31 2010-11-18 Perricone Nicholas V Topical drug delivery using phosphatidylcholine
US20100311696A1 (en) * 2002-05-31 2010-12-09 Perricone Nicholas V Topical skin treatment composition
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
US20050226945A1 (en) * 2004-04-13 2005-10-13 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
US20090324698A1 (en) * 2004-10-18 2009-12-31 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle, the production of this composition and the therapeutic use thereof
US20090214624A1 (en) * 2004-11-29 2009-08-27 The University Of Akron Topical nitric oxide donor devices and methods for their therapeutic use
US20090304815A1 (en) * 2006-02-03 2009-12-10 Giulio Cossu Method of treatment for muscular dystrophy
US20100048520A1 (en) * 2006-03-09 2010-02-25 Salix Pharmaceuticals, Ltd. Rifaximin anti-rectal dysfunction preparation
US7976743B2 (en) * 2006-10-16 2011-07-12 Northwestern University Gas-containing liposomes
US20110104240A1 (en) * 2008-06-24 2011-05-05 Micropharma Limited Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections
US20130029989A1 (en) * 2010-04-15 2013-01-31 The Royal Institution For The Advancement Of Learning/Mcgill University Topical treatments for pain
US20120156163A1 (en) * 2010-12-15 2012-06-21 Susanne Bauman Methods of decreasing sebum production in the skin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Barenholz (Handbook of Nonmedical Applications of Liposomes 1996, CRC Press page 217). *
Daicheng Liu and Fucui Ma (2011). Soybean Phospholipids, Recent Trends for Enhancing the Diversity and Quality of Soybean Products, Prof. Dora Krezhova (Ed.), ISBN: 978-953-307-533-4, InTech, DOI: 10.5772/20986. Available from: http://www.intechopen.com/books/recent-trends-for-enhancing-the-diversity-and-quality-of-soybean-products/soybean-phosphol *
Hasenhuettl, GL. Food Emulsifiers and their Applications, Chapter 2, pages 11-12, 2008; 2 pages. *
Prescott (Methods in cell biology; Academic Press: 1976, volume 14, page 34). *
Shahidi, F., Nutraceutical and Specialty Lipids and their Co-products 2006, CRC Press, page 515; 1 page. *

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050248B2 (en) 2002-05-31 2015-06-09 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US20110123577A1 (en) * 2002-05-31 2011-05-26 Perricone Nicholas V Method Of Delivering Stable Topical Drug Compositions
US9060925B2 (en) 2002-05-31 2015-06-23 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9517179B2 (en) 2011-03-17 2016-12-13 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9937202B2 (en) 2011-03-17 2018-04-10 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9205043B2 (en) 2012-09-19 2015-12-08 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US10034896B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9198931B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9198970B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9198853B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9198930B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9198932B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9198933B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9198854B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9480706B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US10034897B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US10034898B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9968634B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9295638B2 (en) 2012-09-19 2016-03-29 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9968635B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9950004B2 (en) 2012-09-19 2018-04-24 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9844565B2 (en) 2012-09-19 2017-12-19 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9827266B2 (en) 2012-09-19 2017-11-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9795632B2 (en) 2012-09-19 2017-10-24 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9480707B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9480705B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9480709B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9480710B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9480708B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9480711B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9498535B2 (en) 2013-03-13 2016-11-22 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9844506B2 (en) 2013-03-13 2017-12-19 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9439926B2 (en) 2013-03-13 2016-09-13 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9585829B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9636291B2 (en) 2013-03-13 2017-05-02 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9682102B2 (en) 2013-03-13 2017-06-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9687504B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9694029B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9694083B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9700626B2 (en) 2013-03-13 2017-07-11 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9717680B2 (en) 2013-03-13 2017-08-01 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9757467B2 (en) 2013-03-13 2017-09-12 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9827316B2 (en) 2013-03-13 2017-11-28 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9480642B2 (en) 2013-03-13 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9872818B2 (en) 2013-03-13 2018-01-23 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9913793B2 (en) 2013-03-13 2018-03-13 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9931370B2 (en) 2013-03-13 2018-04-03 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9937221B2 (en) 2013-03-13 2018-04-10 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9943562B2 (en) 2013-03-13 2018-04-17 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9956290B2 (en) 2013-03-13 2018-05-01 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10028994B2 (en) 2013-03-13 2018-07-24 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US10034828B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10034944B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10064955B2 (en) 2013-03-13 2018-09-04 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US10071117B2 (en) 2013-03-13 2018-09-11 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10080768B2 (en) 2013-03-13 2018-09-25 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10155048B2 (en) 2013-03-13 2018-12-18 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10188603B2 (en) 2013-03-13 2019-01-29 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10213457B2 (en) 2013-03-13 2019-02-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions

Also Published As

Publication number Publication date
US20150238608A1 (en) 2015-08-27
US7182956B2 (en) 2007-02-27
US20130330380A1 (en) 2013-12-12
JP2005531595A (en) 2005-10-20
US20110130330A1 (en) 2011-06-02
EP1509243A1 (en) 2005-03-02
WO2003101480A1 (en) 2003-12-11
US9050248B2 (en) 2015-06-09
CN100509054C (en) 2009-07-08
CN1671409A (en) 2005-09-21
EP1509243B1 (en) 2017-03-22
AU2003231943B2 (en) 2006-03-16
AU2003231943A1 (en) 2003-12-19
CA2487305A1 (en) 2003-12-11
US20130331319A1 (en) 2013-12-12
US20130331318A1 (en) 2013-12-12
ES2632912T3 (en) 2017-09-18
US20060127469A1 (en) 2006-06-15
EP1509243A4 (en) 2009-06-24
IL165480A (en) 2012-10-31
US20100292139A1 (en) 2010-11-18
IL165480A0 (en) 2006-01-15
US20060105955A1 (en) 2006-05-18
US20040018237A1 (en) 2004-01-29
US20040197391A1 (en) 2004-10-07
US8273711B2 (en) 2012-09-25
US20130330381A1 (en) 2013-12-12
US20150004196A1 (en) 2015-01-01
HK1083009A1 (en) 2006-06-23
US9060925B2 (en) 2015-06-23
US20110123577A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
US9050248B2 (en) Methods of delivering stable topical drug compositions
EP1578325B1 (en) Stable topical drug delivery compositions
US8435942B2 (en) Methods for formulating stabilized insulin compositions
US20100311696A1 (en) Topical skin treatment composition
JP2740465B2 (en) A novel pharmacological dosage form for transdermal administration

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRANSDERMAL BIOTECHNOLOGY, INC., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERRICONE, NICHOLAS V.;REEL/FRAME:019104/0912

Effective date: 20070327

AS Assignment

Owner name: PERRICONE, NICHOLAS V., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POTINI, CHIM;REEL/FRAME:030845/0388

Effective date: 20040106

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION